Connect with us

Health

VTE Risk Higher After Oxford/AstraZeneca COVID-19 Vaccine, Study Affirms – TCTMD

Whether the benefit-risk balance is favorable depends on many factors, but it will be so “in very many cases,” the researcher says.

Published

on

Article feature image

Venous thromboembolic (VTE) events are indeed increased after people get the COVID-19 vaccine from Oxford/AstraZeneca, but the absolute risk is low considering the proven effectiveness of vaccination and the continued spread of SARS-CoV-2 around the globe, researchers report in the BMJ.
After vaccination programs got underway, spontaneous reports of thrombotic events in people who had received the vaccine started coming in, with several European countries pausing its use in March due to the clots….

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending